Latest Sapien Valve Gets EU Go-Ahead, But Germany Will Have To Wait

Edwards Lifesciences plans a "controlled rollout" of its Sapien 3 Ultra transcatheter heart valve replacement in Europe following the CE mark announced Nov. 16. But a patent dispute with Boston Scientific will prevent Edwards from launching it in Germany.

The Sapien 3 Ultra transcatheter aortic heart valve replacement will help improve Edwards Lifesciences Corp. competitive position in the European TAVR market, the company says. But it won't be a factor, at least for the time being, in the largest EU device market, Germany.

The next-gen TAVR device gained a CE mark, Edwards announced Nov. 16. The company is now initiating a "controlled rollout"...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Approvals

More from Policy & Regulation